BioCryst Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on BioCryst Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioCryst Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioCryst Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioCryst Pharmaceuticals Inc (BioCryst) is a biotechnology company that is primarily focused on discovering and developing oral small-molecule and protein therapeutics for rare diseases. The company's main activities include leveraging structure-guided drug design to create therapies for conditions such as hereditary angioedema (HAE) and complement-mediated diseases. BioCryst's notable products include ORLADEYO, an oral plasma kallikrein inhibitor, and RAPIVAB, an intravenous neuraminidase inhibitor. BioCryst operates through a network of regional offices and collaborates with healthcare professionals to distribute its therapies globally. The company has its operations in the US and Ireland. BioCryst is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
4505 Emperor Blvd Ste 200, Durham, North Carolina, 27703-8457
Website
www.biocryst.com
Telephone
1 919 8591302
No of Employees
435
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BCRX (NASD)
Revenue (2024)
$874.8M
94.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
396.9%
(2024 vs 2023)
Market Cap*
$2.2B
Net Profit Margin (2024)
XYZ
252.9%
(2024 vs 2023)
* As of and is in US$
BioCryst Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Peramivir Injection: Acute Uncomplicated Influenza and Uncomplicated seasonal Influenza | Peramiflu |
| Berotralstat Oral Capsule: Prophylactic Hereditary Angioedema (HAE) | Rapivab |
| Pipeline | Orladeyo |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company secured approval from the U.S. Food and Drug Administration for its New Drug Application for the use of an oral pellet formulation of once-daily ORLADEYO (berotralstat). |
| 2025 | Divestiture | In October, the company sold its European ORLADEYO (berotralstat) business to Neopharmed Gentili. |
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company acquired Astria Therapeutics, Inc. for US$700 million. |
Competitor Comparison
| Key Parameters | BioCryst Pharmaceuticals Inc | Merck & Co Inc | GSK plc | Boehringer Ingelheim International GmbH | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Germany | United States of America |
| City | Durham | Rahway | London | Ingelheim am Rhein | Foster City |
| State/Province | North Carolina | New Jersey | England | Rheinland-Pfalz | California |
| No. of Employees | 435 | 75,000 | 66,841 | 54,300 | 17,000 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Charlie K. Gayer | Chief Executive Officer; Director; President | Executive Board | 2026 | 55 |
| Babar Ghias | Chief Financial Officer | Senior Management | 2025 | 47 |
| Philip George | Chief Strategy Officer | Senior Management | 2022 | - |
| Alane P. Barnes | Chief Legal Officer; Secretary | Senior Management | 2018 | 60 |
| Stephanie Angelini | Chief People Officer | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer